KENZIE SIMS: Open Payments
NPI 1043974678 · NATCHEZ, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$784 in 41 payments from 11 companies in 2025. Trend: 2023 $0 · 2024 $502 · 2025 $784
Food & beverage: $784
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 21 | $375 |
| AstraZeneca Pharmaceuticals LP | 5 | $86 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $58 |
| Astellas Pharma US Inc | 2 | $47 |
| Novo Nordisk Inc | 2 | $46 |
| Sumitomo Pharma America, Inc. | 2 | $39 |
| GlaxoSmithKline, LLC. | 2 | $38 |
| Exact Sciences Corporation | 1 | $27 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $25 |
| Ardelyx, Inc. | 1 | $21 |
Products named: QULIPTA, CREON, LINZESS, JARDIANCE, BREZTRI, Veozah, GEMTESA, TRELEGY ELLIPTA.
Industry payments across MS — which companies pay providers there.
